MSH2 and cancer: Systematic analysis of mutation rates in 30,191 cancer patients across 103 cancer types revealed a somatic CpG hypermutator phenotype, associated with MSH2/MSH6 deficiency, an increase in TP53 hotspot mutations and associated improved response to immune checkpoint inhibitors.